Evidence map›Paper›PMID 33027365›Full record

ArticleArquivos brasileiros de cardiologia2020

Cardiovascular Risk and Statin Eligibility in Primary Prevention: A Comparison between the Brazilian and the AHA/ACC Guidelines.

Fernando H Y Cesena, Viviane A Valente, Raul D Santos, Márcio S Bittencourt

Full text read
In one paragraph

Article in Arquivos brasileiros de cardiologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Statin Associated With Physical Training: A Perfect Combination.Arquivos brasileiros de cardiologia · 2021
    Article
  2. Article
  3. Article
  4. Changes in Our Times and in Cholesterol Targets.Arquivos brasileiros de cardiologia · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Fernando H Y CesenaHospital Israelita Albert Einstein, São Paulo, SP - Brasil.ORCID 0000-0002-1051-9434
Viviane A ValenteHospital Israelita Albert Einstein, São Paulo, SP - Brasil.
Raul D SantosHospital Israelita Albert Einstein, São Paulo, SP - Brasil.
Márcio S BittencourtHospital Israelita Albert Einstein, São Paulo, SP - Brasil.ORCID 0000-0002-3711-1754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferences between the updated versions of the Brazilian Guideline on Dyslipidemias and the American Heart Association (AHA)/American College of Cardiology (ACC) Cholesterol Guideline regarding cardiovascular risk stratification and statin eligibility are unknown.

objectivesTo compare cardiovascular risk categorization and statin eligibility based on the Brazilian guideline with those based on the AHA/ACC guideline in primary prevention patients.

methodsWe retrospectively analyzed individuals aged 40-74 years without high-risk conditions, with LDL-c 70 to < 190 mg/dL, not on lipid-lowering drugs, who underwent routine clinical assessment. Cardiovascular risk was stratified according to the Brazilian and the AHA/ACC guidelines. Subjects were considered eligible for statin therapy if LDL-c was at least 30 mg/dL above the target for the cardiovascular risk (Brazilian guideline) or the 10-year atherosclerotic cardiovascular disease risk was ≥7.5% (AHA/ACC guideline). A p-value < 0.05 was considered statistically significant.

resultsThe study sample consisted of 18,525 subjects (69% male, age 48 ± 6 years). Among subjects considered at intermediate or high risk by the Brazilian guideline, over 80% would be in a lower risk category by the AHA/ACC guideline. Among men, 45% and 16% would be statin eligible by the Brazilian and the AHA/ACC guidelines criteria, respectively (p < 0.001). Among women, the respective proportions would be 16% and 1% (p < 0.001). Eighty-two percent of women and 57% of men eligible for statins based on the Brazilian guideline criterion would not be eligible according to the AHA/ACC guideline criterion.

conclusionsCompared with the AHA/ACC guideline, the Brazilian guideline classifies a larger proportion of primary prevention patients into higher-risk categories and substantially increases statin eligibility. (Arq Bras Cardiol. 2020; 115(3):440-449).

Indexed as

CardiologyCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsAdultAgedAmerican Heart AssociationBrazilFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPrimary PreventionRetrospective StudiesRisk AssessmentRisk FactorsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID33027365
PMCPMC9363097

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.